Researcher
Linos Vandekerckhove
- Keywords:Long-non-coding, RNA, Interactome, HIV, HIV Cure, HIV reservoir, HIV animal models
- Disciplines:Virology, Transcription and translation, Cellular interactions and extracellular matrix
Affiliations
- Department of Internal Medicine and Pediatrics (Department)
Member
From1 Oct 2018 → Today - Department of Diagnostic Sciences (Department)
Member
From1 Oct 2018 → Today - Department of Internal medicine (Department)
Member
From1 Oct 2010 → 30 Sep 2018 - Department of Clinical chemistry, microbiology and immunology (Department)
Member
From1 Oct 2008 → 30 Sep 2018
Projects
1 - 10 of 37
- Generation of a dynamic spatial map of the cellular landscape of HIV-infected gut and its application in unraveling the role of tissue-resident T cells in HIVFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- HIV Nanoheroes: novel CRISPR/Cas9-based CD4+ cell-specific HHV-7 vectors to cure HIVFrom1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- Selection and Evolution of HIV-1 reservoir cells in blood and tissues - YEAR 3From1 Sep 2023 → TodayFunding: Other international institutions, not mentioned elsewhere
- Defining molecular pathways triggered by IL-10 and TGFb that drive HIV integrationand persistence in Tfh cells in lymph nodesFrom1 Jul 2023 → TodayFunding: Other international institutions, not mentioned elsewhere
- Feasibility evaluation of anti-HIV Antibody-secreting Chimeric Antigen Receptor T cells as a potential cure in acute seroconvertersFrom30 Mar 2023 → 29 Mar 2024Funding: Foreign public sponsor
- Functional analysis of T cells infiltrating the lungs of severely ill COVID-19 patientsFrom1 Jan 2023 → 31 Dec 2023Funding: Foundations, funds and other with scientific goal
- ABSL3 mice housing system to develop new therapies against virulent pathogensFrom15 Dec 2022 → TodayFunding: BOF - scientific equipment program
- How do ILCs go wrong: unravelling the mechanisms of ILC depletion and functions in HIV infectionFrom1 Nov 2022 → TodayFunding: FWO fellowships
- A novel CRISPR/Cas9-based nanomedicine strategy targeting CD4+ cells to cure HIVFrom1 Nov 2022 → TodayFunding: FWO Strategic Basic Research Grant
- HIV-1 DNA based enrichment of intact proviruses: finding a helix in a haystackFrom1 Nov 2022 → TodayFunding: FWO Strategic Basic Research Grant
Publications
31 - 40 of 132
- Single cell epigenetic visualization assay(2021)
Authors: Sam Kint, Wim Van Criekinge, Linos Vandekerckhove, Winnok H De Vos, Karol Bomsztyk, Diane S Krause, Oleg Denisenko
- Interferon-mediated long non-coding RNA response in macrophages in the context of HIV(2020)
Authors: Tinus Schynkel, Matthew A. Szaniawski, Adam M. Spivak, Alberto Bosque, Vicente Planelles, Linos Vandekerckhove, Wim Trypsteen
- Emerging PCR-based techniques to study HIV-1 reservoir persistence(2020)
Authors: Laurens Lambrechts, Basiel Cole, Sofie Rutsaert, Wim Trypsteen, Linos Vandekerckhove
- Underestimated effect of intragenic HIV-1 DNA methylation on viral transcription in infected individuals(2020)
Authors: Sam Kint, Wim Trypsteen, Ward De Spiegelaere, Eva Malatinková, Sabine Kinloch-de Loes, Tim De Meyer, Wim Van Criekinge, Linos Vandekerckhove
- Week 48 resistance analyses of the once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials(2020)
Authors: Erkki Lathouwers, Eric Y Wong, Kimberley Brown, Bryan Baugh, Anne Ghys, John Jezorwski, El Ghazi Mohsine, Erika Van Landuyt, Magda Opsomer, Sandra De Meyer, et al.
Pages: 48 - 57 - Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1(2020)
Authors: J. M. Eberhard, M. Angin, C. Passaes, M. Salgado, V. Monceaux, E. Knops, G. Kobbe, B. Jensen, M. Christopeit, N. Kröger, et al.
- Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients(2020)
Authors: C Orkin, JJ Eron, J Rockstroh, D Podzamczer, S Esser, Linos Vandekerckhove, E Van Landuyt, E Lathouwers, V Hufkens, J Jezorwski, et al.
Pages: 707 - 718 - Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response : a sub-study of the NEAT001/ANRS143 randomized trial(2020)
Authors: Laura Dickinson, Rohan Gurjar, Andrew Owen, Antonio DU+2019Avolio, Gerd Fäetkenheuer, Linos Vandekerckhove, Giovanni Di Perri, the NEAT001/ANRS143 Study Group, Siegfried Schwarze, Genevieve Chene, et al.
Pages: 628 - 639 - Predictors of virological failure in HIV-1-infected patients switching to dolutegravir maintenance monotherapy(2019)
Authors: Ingeborg E.A. Wijting, Sofie Rutsaert, Casper Rokx, David M. Burger, Annelies Verbon, Jeroen J. A. van Kampen, Charles A. B. Boucher, Bart J. A. Rijnders, Linos Vandekerckhove
Pages: 63 - 68 - Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks : results of the DRIVE-SHIFT trial(2019)
Authors: Margaret Johnson, Princy Kumar, Jean-Michel Molina, Giuliano Rizzardini, Pedro Cahn, Markus Bickel, Josep Mallolas, Yan Zhou, Cristiana Morais, Sushma Kumar, et al.
Pages: 463 - 472
Patents
1 - 1 of 1